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Abstract 
Background: Sodium glucose co‑transporter2 inhibitors reduce the incidence of cardiovascular events in patients 
with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated 
the effects of long‑term treatment with canagliflozin on biochemical and immunohistochemical markers related to 
atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout (Apo‑E(−/−)) mice.
Methods: At the age of 5 weeks, mice were switched from normal to a high‑fat diet. After 5 weeks, Apo‑E(−/−) mice 
were divided into control‑group (6 mice) treated with 0.5% hydroxypropyl methylcellulose and Cana‑group (7 mice) 
treated with canagliflozin (10 mg/kg per day) per os. After 5 weeks of intervention, animals were sacrificed, and heart 
and aorta were removed. Sections stained with hematoxylin–eosin (H&E) were used for histomorphometry whereas 
Masson’s stained tissues were used to quantify the collagen content. Immunohistochemistry to assess MCP‑1, CD68, 
a‑smooth muscle actin, MMP‑2, MMP‑9, TIMP‑1 and TIMP‑2 expression was carried out and q‑PCR experiments were 
performed to quantify mRNA expression.
Results: Canagliflozin‑group mice had lower total‑cholesterol, triglycerides and glucose levels (P < 0.01), while heart 
rate was significantly lower (P < 0.05). Histomorphometry revealed that one in seven Cana‑group mice versus four in 
six control mice developed atheromatosis, while aortic root plaque was significantly less, and collagen was 1.6 times 
more intense in canagliflozin‑group suggesting increased plaque stability. Immunohistochemistry revealed that 
MCP‑1 was significantly less expressed (P < 0.05) in the aortic root of canagliflozin‑group while reduced expression of 
a‑actin and CD68 was not reaching significance (P = 0.15). VCAM‑1 and MCP‑1 mRNA levels were lower (P = 0.02 and 
P = 0.07, respectively), while TIMP‑1/MMP‑2 ratio expression was higher in canagliflozin‑group approaching statistical 
significance (P = 0.07).
Conclusions: Canagliflozin attenuates the progression of atherosclerosis, reducing (1) hyperlipidemia and hyper‑
glycemia, and (2) inflammatory process, by lowering the expression of inflammatory molecules such as MCP‑1 and 
VCAM‑1. Moreover, canagliflozin was found to increase the atherosclerotic plaque stability via increasing TIMP‑1/
MMP‑2 ratio expression.
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Background
According to data from the World Health Organization 
(WHO), over 3 million people die worldwide from dia-
betes and its related complications every year, mainly due 
to cardiovascular disease (CVD) [1]. Despite paucity of 
information regarding the aetiopathogenesis of T2DM 
related cardiovascular complications, the toxicity of high 
blood glucose to the endothelium and other cells of the 
vessels seem to play an important role in the development 
of atherosclerosis and subsequent CVD. Atherosclerosis 
represents a systemic inflammatory process which impli-
cates both cells of immune system and those of vessel 
wall. The basic pathologic lesion is atheromatous plaque. 
The atherogenic process evolves in different stages, start-
ing from the endothelium activation/dysfunction and 
resulting in plaque vulnerability and rupture [2]. At the 
earlier stages of the atheromatous process, endothelial 
dysfunction/activation is characterized among others by 
increased expression of adhesion molecules and inflam-
matory molecules such as VCAM-1, ICAM-1 and MCP-1 
and IL-6 by the endothelial and vascular smooth mus-
cle cells. During the later stages of plaque rupture and/
or erosion, among other factors, the metalloproteinases 
MMP-2, MMP-9 as well as their inhibitors TIMP-1 and 
TIMP-2; both expressed in endothelial cells and vascu-
lar smooth muscle cells, seem to play a critical role, since 
they regulate the collagen degradation of the extracellular 
matrix (ECM) [3]. Monocyte chemoattractant protein-1 
(MCP-1) has been postulated to be a direct mediator of 
plaque instability [4].
SGLT2 inhibitors (SGLT2i) are a new class of oral 
anti-diabetic drugs, targeting the sodium-glucose co-
transporter 2 which is the main glucose transporter of 
the kidney, and is responsible for reabsorption of 90% of 
glucose from primary urine. SGLT2 inhibition reduces 
the reabsorption of glucose and therefore enhances uri-
nary glucose excretion, consequently decreasing both 
fasting and postprandial hyperglycemia and preventing 
glucotoxicity, and consequently hyperglycemia-induced 
damage. However, pleiotropic effects of these agents have 
already emerged [5].
Recent clinical trials amongst them CVD-REAL Nordi, 
EMPA-REG OUTCOME and canagliflozin CANVAS 
program have shown that SGLT2 inhibitors (dapagliflo-
zin, empagliflozin, canagliflozin) use is associated with 
reduced cardiovascular disease and cardiovascular mor-
tality compared with use of other glucose-lowering drugs 
in patients with T2DM, even though hemoglobin A1c 
(HbA1c) difference between randomized groups was 
marginal [6–8]. This suggests direct beneficial effects of 
SGLT2i on CVD risk besides the indirect effects attrib-
uted to better glycemic control, blood pressure or actions 
on extra-cardiovascular tissues such as adipose tissue.
Interestingly, recent studies have shown that SGLT-2 
inhibitors can reduce pro-inflammatory IL-6, MCP-1 
and ICAM-1 expression in blood vessels of rodent dia-
betic models, yet the molecular mechanisms remain 
largely unknown. To this direction, Mancini and col-
laborators reported recently that canagliflozin, but not 
empagliflozin or dapagliflozin can activate AMPK and 
inhibit IL-1β-stimulated secretion of IL-6 and mono-
cyte chemoattractant protein-1 (MCP-1) in cultured 
human endothelial cells, while AMPK-independent 
mechanisms were also recognized [9]. Another research 
group has currently investigated the anti-inflammatory 
effects of SGLT-2 inhibitors in immune cells such as 
macrophages/monocytes both involved in the athero-
genic process. According to their results, canagliflo-
zin at clinically-relevant concentrations exerted the 
most potent inhibition-compared to other SGLT-2 
inhibitors-of production and release of inflammatory 
factors IL1a, IL-6 and TNF-α [10]. These effects medi-
ated by inhibiting intracellular glycolysis, enhancing 
autophagy, and promoting p62-mediated IL-1 degrada-
tion. Of note, enhanced autophagy and p62 levels might 
be mediated by increasing AMPK and NFκB activities, 
respectively; whether the above anti-inflammatory 
effects of canagliflozin were associated with SGLT2 
should be further investigated [10].
Paradoxically, today there are more clinical than 
experimental data regarding the beneficial effects of 
SGLT2i on CVD, evaluating endothelial function, arte-
rial stiffness, atherogenic cholesterols in patients with 
DM type 2 etc. [11–13]; however, although various 
SGLT2i such as empagliflozin, dapagliflozin, ipragliflo-
zin and luseogliflozin have been evaluated in animal 
experimental studies regarding their the anti-ather-
ogenic effects, there is paucity of evidence regarding 
canagliflozin.
To this context, we investigated for the first time the 
effects of long-term treatment with canagliflozin on 
atherosclerosis development in the aorta of  APOE(−/−) 
mice as well as on biochemical and immunohistochem-
ical markers linked to atherosclerosis.
Materials and methods
Animals
APOE(−/−) mice (on the genetic background C57BL/6) 
were originally purchased from “The Jackson Labora-
tory” and bred in the animal facility of National and 
Kapodistrian University of Athens. Mice were kept at 
specific pathogen free (SPF) controlled environment 
(22–26  °C temperature, 40–60% humidity and 12  h 
light/dark cycle).
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Experimental protocols
Thirteen male  APOE−/− mice were kept on a standard 
rodent chow. At the age of 5 weeks mice were switched 
to high fat diet (20–23% by weight; 40–45% kcal from fat) 
containing cholesterol (0.2% total).
After 5  weeks, mice were randomly divided into two 
groups (1) canagliflozin-group 10  mg/kg/day (n = 7) 
administered orally by gavage, and (2) control-group 
(n = 6) administered the same volume of 0.5% hydroxy-
propyl methylcellulose/day (vehicle), via gavage. After 
5  weeks of oral treatment with canagliflozin or vehicle, 
mice were sacrificed under isoflurane anesthesia by tran-
section of the diaphragm and, the aorta along with heart 
were rapidly excised. Food intake and body weight were 
measured once weekly over a period of 10 weeks. Blood 
glucose levels were also measured after 8–10  h fast via 
tail puncture at baseline, before canagliflozin/vehicle 
oral administration, once during experiment (3  week) 
and before experiment endpoint. Canagliflozin was pur-
chased from Selleck Chemand dissolved in 0.5% hydroxy-
propyl methylcellulose.
Mice blood pressure measurement
Blood pressure was measured once at baseline, before 
canagliflozin oral administration began and once 
before sacrificing animals. Mice were acclimatized to 
the restrainer on a warming pad for 2 consecutive days 
before final measurements. Measurements were per-
formed in quiet environment to avoid causing mice 
anxiety. Blood pressure measurements were performed 
(15–25 measurements/mouse) using a computerized 
non-invasive tail-cuff system (CODAs, Kent Scientific, 
USA). All measurements are expressed as mean value of 
heart rate, systolic and diastolic blood pressure.
Serum analysis of biochemical parameters
Blood was drawn once before the onset of canagliflozin 
administration from the facial vein and once by heart 
puncturing after sacrificing mice. Serum glucose, choles-
terol, triglycerides, and HDL- and LDL-cholesterol levels 
were determined using a dedicated autoanalyzer.
RNA isolation and real time PCR
Total RNA was extracted from fresh frozen aorta using 
RNeasy kit (Qiagen). Extracted mRNA was then reverse 
transcribed into cDNA using the iScript cDNA synthesis 
kit (Bio-Rad). Real-time PCR analysis was performed as 
described previously [14]. The expression of Matrix Met-
alloproteinase (MMP-2 and MMP-9) and their inhibi-
tors (TIMP-1 and TIMP-2), IL-6, intercellular adhesion 
molecule 1 (ICAM-1), vascular cell adhesion molecule 
1 (VCAM-1) and monocyte chemotaxis protein (MCP-
1) was measured using  Luna® Universal qPCR Master 
Mix (New England Biolabs) on a CFX96 (Bio-RAD). The 
sequences of primers used for RT-PCR analysis in this 
study are listed in Table 1. A melting curve analysis was 
performed to confirm the specificity of qPCR products. 
Fold-changes were calculated using the  2−∆∆Ct method 
and were normalized against 18s rRNA expression. All 
reactions were performed in triplicates and repeated 
three times.
Histochemistry and immunohistochemistry
Quantification of atherosclerotic lesion area
Aortic tissues were fixed and embedded in paraffin. 
The 4-μm-thick sections were stained with hematoxy-
lin–eosin (H&E) and used for histopathological analysis 
whereas Masson’s trichrome stained sections were used 
to quantify tissue section’s collagen content. The degree 
of pathological changes was evaluated microscopically 
by measuring the area of atheromatous plaques. Results 
are reported as the percentage of the neointima area con-
taining the lesion. Threshold was set and the positively 
stained area for each histochemical stain was automati-
cally calculated and then the percent of the positively 
stained area to the total cross-sectional vessel wall area 
Table 1 qPCR primer sequences used in this study
Target gene Primer sequence (forward) Primer sequence (reverse)
MMP‑2 5′‑CCC TCA AGA AGA TGC AGA AGTTC‑3′ 5′‑TCT TGG CTT CCG CAT GGT ‑3′
MMP‑9 5′‑CGT CGT GAT CCC CAC TTA CT‑3′ 5′‑AAC ACA CAG GGT TTG CCT TC‑3′
TIMP‑1 5′‑GCA TGG ACA TTT ATT CTC CAC TGT ‑3′ 5′‑TCT CTA GGA GCC CCG ATC TG‑3′
TIMP‑2 5′‑TTC CGG GAA TGA CAT CTA TGG‑3′ 5′‑GGG CCG TGT AGA TAA ACT CGAT‑3′
MCP‑1 5′‑GCA TCC ACG TGT TGG CTC A‑3′ 5′‑CTC CAG CCT ACT CAT TGG GATCA‑3′
IL‑6 5′‑CCT CTG GTC TTC TGG AGT ACC‑3′ 5′‑ACT CCT TCT GTG ACT CCA GC‑3′
ICAM‑1 5′‑GGT TCT CTG CTC CTC CAC AT‑3′ 5′‑CCT TCC AGG CTT TCT CTT TG‑3′
VCAM‑1 5′‑CTT CCA GAA CCC TTC TCA G‑3′ 5′‑GGG ACC ATT CCA GTC ACA CTTC‑3′
18S rRNA 5′‑GTT CCG ACC ATA AAC GAT GCC‑3′ 5′‑TGG TGG TTG CCC TTC CGT CAAT‑3′
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or intimal plaque lesion area was reported. Plaque area 
analysis was carried out using Image Pro Plus software 
version 5.1 (Media Cybernetics, Inc.).
Immunohistochemistry
For immunohistochemistry, all sections were deparaffi-
nized at 60  °C. Antigen retrieval was performed using 
citrate buffer (PH.6.0) for 7  min at 100  °C followed by 
blocking with normal goat serum (CST, 5425S) for 1  h. 
Slides were then incubated with appropriate concentra-
tion of primary antibodies against CD68 (ZYTOMED, 
MSK055), α-smooth muscle actin (ZYTOMED, 
MSK030), MCP-1 (ACRIS, AM32136PU-N), MMP-2 
(Proteintech Group, 103732-AP), MMP-9 (Proteintech 
Group, 10375-2-AP) and their inhibitors TIMP-1 (Santa 
Cruz Biotechnology, sc-21734) and TIMP-2 (Santa Cruz 
Biotechnology, sc-21735) followed by incubation with 
corresponding secondary antibody conjugated to horse-
radish peroxidase (ZYTOMED, ZUC053-100) and visu-
alized by applying DAB (CST.8059P). All slides were 
counterstained with hematoxylin and integral absorbance 
was examined under light microscope and results were 
quantified using Image Pro Plus software version 5.1 
(Media Cybernetics, Inc.). A positive tissue control was 
used to ensure the specificity of antibodies used in this 
study.
Statistical analysis
Normality of quantitative data distribution was assessed 
using Shapiro–Wilk test. Student’s t-test, Welch’s t-test 
or Mann–Whitney U test were used for comparisons 
between two groups with quantitative data as appro-
priate. Chi square test or Fisher’s exact test were used 
for comparisons among groups with qualitative data as 
appropriate. Correlations between quantitative param-
eters were tested with Pearson’s correlation coefficient 
or Spearman’s rank correlation coefficient as appropri-
ate. All tests were two-tailed, and results were considered 
statistically significant if the P-value was < 0.05. Statistical 
analysis was performed using the 23rd edition of statisti-
cal package for social sciences (SPSS) (IBM Corporation, 
Armonk, NY, USA).
Results
Oral administration of canagliflozin for 5 weeks improved 
heart rate and biochemical/metabolic parameters 
associated with atherosclerosis
No significant difference in daily food intake was 
observed between the two groups. Nevertheless, body 
weight was significantly increased in both groups fol-
lowing HFD and 5  weeks of oral canagliflozin/vehicle 
administration as compared to the value measured at 
experiment baseline. No significant difference in weight 
gain was observed between canagliflozin and control 
group (Additional file 1: Figure S1).
Fasting blood glucose (8 h of fasting) and serum lipid 
levels were measured before canagliflozin/vehicle oral 
administration as well as at the end of intervention 
period. A significant reduction in glucose, total choles-
terol, LDL-cholesterol and triglyceride levels (P < 0.01) 
were observed in canagliflozin group (Fig. 1). After treat-
ment with canagliflozin, glucose levels returned to nor-
mal range, contrary to placebo group where glucose 
increased significantly above normal range with glucose 
level progression to diabetes range (P < 0.001).
At the end of intervention period, total cholesterol, 
glucose and triglyceride levels were significantly lower in 
Cana-group (P = 0.01, P = 0.001, P = 0.02 respectively). 
Moreover, diastolic blood pressure values was signifi-
cantly higher in the control group at experiment end-
point (P = 0.05) (Additional file 2: Table S1).
At the end of canagliflozin/placebo oral treatment, 
there was a significant difference from baseline in fasting 
glucose (P < 0.001), triglycerides (P < 0.01), and total cho-
lesterol (P < 0.05) between groups. Mean ± SD changes in 
LDL-, HDL-cholesterol and creatinine levels from base-
line were similar in both groups (Fig. 2).
Canagliflozin significantly reduced heart rate 
(**P ≤0.01) (Fig.  3), whereas no significant change was 
observed in the control group (Fig. 3a). This finding was 
confirmed by comparing heart rate changes from base-
line (value measured before onset of canagliflozin/vehicle 
oral administration) between the two groups. (*P ≤ 0.05) 
(Fig.  3b). As it is shown in Additional file  2: Table  S1 
post-treatment heart rate was reduced in Cana-group 
compared to control-group approaching statistical sig-
nificance (P = 0.076).
Canagliflozin reduces atherosclerosis lesion formation 
and increases collagen content
Canagliflozin administration for 5  weeks significantly 
reduced atherogenesis process. One mouse in the Cana-
group (7 mice) developed atherosclerotic plaque, con-
trary to four mice with atherosclerotic plaque in the 
control-group (6 mice). Atherosclerotic plaque presence 
was assessed using H&E staining (representative Fig. 4a). 
Atherosclerotic lesion area was quantified measuring the 
percentage of lumen area covered by total plaque area in 
all aortic root sections, and the mean plaque area (± SD) 
was then calculated for each group (Fig. 4b). The forma-
tion of atherosclerosis was significantly lower (by 25%) 
in Cana-group (P < 0.05). Masson Trichrome staining 
showed that atherosclerotic lesions in the Cana-group 
had greater collagen content (1.6 times more) compared 
to  placebo group (P < 0.1). Images and quantitative data 
are shown in Fig. 4.
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Fig. 1 Serum lipid and fasting blood glucose levels in Cana‑ and control‑groups after 5 weeks of canagliflozin/vehicle oral administration. 
Significant reduction in total cholesterol, triglyceride, LDL‑cholesterol and fasting blood glucose levels was observed in Cana‑group at the end of 
experimental procedure compared to baseline. Fasting glucose was the only significantly increased parameter observed in the control group at the 
end of intervention. Data are shown as mean ± SD (***P ≤ 0.001, **P ≤ 0.01)
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Fig. 2 Fasting glucose, total cholesterol and triglyceride changes from baseline. Significant changes were detected from baseline in fasting glucose, 
total cholesterol and triglyceride between study groups. Data are shown as mean ± SD (***P < 0.001, **P < 0.01, *P < 0.05)
Page 6 of 12Nasiri‑Ansari et al. Cardiovasc Diabetol  (2018) 17:106 
Canagliflozin reduced the expression of inflammatory 
molecules and improved metalloproteinase profile
To evaluate the effect of canagliflozin treatment on 
the expression of inflammatory (IL-6, MCP-1), adhe-
sion molecules (ICAM-1, V-CAM-1), matrix metal-
loproteinases (MMP-2, MMP-9) and their inhibitors 
(TIMP-1, TIMP-2), total RNAs were isolated from the 
thoracic aorta and analyzed using real-time quantita-
tive RT-PCR.
We demonstrate that oral canagliflozin administration 
significantly reduces VCAM-1 mRNA levels (P = 0.01) 
while marginally induces TIMP-1 and decreases MCP-1 
mRNA expression levels (P = 0.07). Canagliflozin treat-
ment causes no significant alteration in IL-6, ICAM-1, 
MMP-2, MMP-9 and TIMP-2 mRNA levels compared to 
controls (Fig. 5a). A balance between MMPs and TIMPs 
is known as an indicator of MMPS overall collagenolytic 
activity. To this end, TIMP-1/MMP-2 ratio mRNA levels 
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Fig. 3 Canagliflozin/vehicle oral administration effect on heart rate of  APOE(−/−) mice. a 5 weeks of canagliflozin intervention led to significant 
reduction of heart rate (**P < 0.01) while no significant difference was observed in the control group. b Heart rate changes from baseline were 
significantly different between Cana‑ and control‑groups (*P < 0.05)
Fig. 4 Atherosclerotic plaque extension among  APOE(−/−) mice on western diet treated with canagliflozin (Cana‑group) or vehicle (control‑group). 
a Selected 4 μm section images from the aortic root stained with H&E and Masson trichrome. Formation of atherosclerotic plaque was examined 
using H&E staining while histological examination of atherosclerotic plaque collagen content was assessed using Masson trichrome staining. 
b Quantification of plaque area is shown as a percentage of lumina stenosis by thickened intima. Collagen content was measured using 
quantification of Masson trichrome positive area over complete plaque area. Values are shown as mean ± SD and *P < 0.05. Original magnification 
×40. H&E indicates hematoxylin and eosin
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was measured. Our findings demonstrate that TIMP-1/
MMP-2 ratio mRNA level was higher in Cana-group 
(Fig. 5b), while approaching significance (P = 0.07). Aor-
tic root section immunohistochemistry revealed that 
smooth muscle (α-actin) and macrophage (CD68) cells 
content from atherosclerotic plaques were marginally 
higher in the control group (P < 0.1). Moreover, treatment 
with canagliflozin led to significant reduction in MCP-1 
expression (P < 0.05) and a marginal increase in athero-
sclerotic plaque TIMP-1 expression (P < 0.1). Images and 
quantitative data are shown in Fig. 6.
Discussion
Canagliflozin is an intermediate-acting SGLT2i with 
proven clinical efficacy regarding glycemic control, blood 
pressure and weight reduction, in patients with T2DM 
irrespective of the degree of CVD history or risk factors 
[15]. In the present study, we investigated the effect of 
canagliflozin on atherosclerosis formation and demon-
strated for the first time, that 5 week canagliflozin admin-
istration attenuates atheromatous process in  APOE(−/−) 
mice fed an atherogenic diet for 10 weeks enough for ath-
eroma to be formed [16].
We evaluated the impact of treatment with canagliflo-
zin in established atherosclerosis risk factors and were 
able to demonstrate the anticipated effect on fasting 
glucose level. In fact, the control-group fed with west-
ern diet for 10 weeks, had significantly increased fasting 
blood glucose level while canagliflozin administration 
reversed this effect. In contrast, Terasaki et al. [17] found 
that western diet fed mice for 4 weeks retained their glu-
cose levels in the normal range, an effect that is probably 
attributed to strain background differences [18]. It should 
be noted that the majority of available animal data on 
glucose-lowering effects of SGLT2 inhibitors have used 
models of streptozotocin-induced diabetic models.
Canagliflozin administration combined with athero-
genic diet, did not lead to reduced weight. On the con-
trary, there was a statistically significant increase, without 
differences between the two groups either in weight or in 
daily food intake. Although weight-loss effects of cana-
gliflozin have been demonstrated in clinic trials, with 
reduction in both subcutaneous and visceral adipose 
tissue dose-dependently [19, 20], animal studies have 
yielded conflicting results. Administration of canagliflo-
zin 30 mg/kg/day for 4 weeks reduced the weight gain in 
diet-induced obese mice fed with high-fat diet [21]. In 
a recent study by Ji et  al. [22] administration of 60  mg/
kg/day canagliflozin for 4  weeks in mice fed with high-
fat diet containing 6% fat, reduced significantly the body 
weight, via reduction of PPRAγ in the liver; interestingly, 
in line with our results, this effect was not achieved with 
the lower dose of 15 mg/kg/day. Naznin et al. [23] found 
that canagliflozin at dose of 30  mg/day attenuated the 
body weight gain by promoting caloric loss and suppres-
sion of obesity-related inflammation in both the nervous 
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Fig. 5 a VCAM‑1, MCP‑1 and TIMP‑1 mRNA expression from thoracic aorta of mice treated with canagliflozin (10 mg/kg/day—5 weeks) and 
control‑group (vehicle—5 weeks). VCAM‑1 mRNA expression was significantly decreased in Cana‑group as well as MCP‑1, while TIMP‑1 mRNA 
expression was increased. b TIMP‑1/MMP‑2 ratio mRNA was also increased in Cana‑group (compared to control‑group) approaching the borderline 
of significance (P = 0.07). Data are presented as mean (**P < 0.01)
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system and skeletal muscle. Regarding the effect of other 
SGLT2 is on body weight, administration of dapagliflozin 
for 12 weeks in non-diabetic  APOE(−/−) mice did not sig-
nificantly reduce weight [24]. In another study, dapagli-
flozin did not change the weight of  APOE(−/−) mice, with 
or without diabetes [17] while ipragliflozin 1 mg/kg/day 
for 4 weeks, reduced significantly the weight of db/db rats 
[17]. Empagliflozin for 8  weeks decreased body weight 
and particularly adipose tissue in  APOE(−/−) mice, while 
did not affect the weight of ZDF rats (type 2 diabetes 
model) [25]. Among the involved mechanisms, decrease 
of the subcutaneous fat mass and the size of visceral adi-
pocytes as well as enhanced fat utilization and browning, 
attenuation of obesity-induced inflammation and insu-
lin resistance by polarizing M2 macrophages in WAT 
and liver have been described [26, 27]. Although, the 
daily food intake and body weight changes did not differ 
between our two groups, canagliflozin exerted beneficial 
effects on lipid profile, reducing total cholesterol and tri-
glycerides. As with body weight, there are also inconsist-
ent results concerning the effects of SGLT-2 inhibitors on 
lipids, either reducing or not affecting total cholesterol, 
LDL-cholesterol and triglycerides, however data exam-
ining the effects specifically of this dose of canagliflozin 
on lipid profile have not been assessed previously [22, 24, 
25, 28–30]. Conflicting results concerning the effects of 
SGLT-2i on body weight and lipid profile may be due to 
differences in animal models used (i.e. mice, rats, dia-
betic, non-diabetic, atherosclerotic, obese etc.), different 
drugs used (including different doses and durations of 
treatment), and/or different diets.
Although clinical studies have proved the antihyper-
tensive effects (SBP, DBP, pulse pressure and mean arte-
rial pressure) of canagliflozin [12], herein we find just 
a borderline reduction of diastolic pressure. However, 
canagliflozin reduces significantly heart rate. This could 
be attributed to a possible decrease in insulin levels as 
a result of the glucose-lowering effects of canagliflozin 
since it is well known that insulin increases sympathetic 
activity [31]. Although we did not measure insulin lev-
els, reduction in serum insulin has been reported fol-
lowing administration of empagliflozin for 7  weeks in a 
Fig. 6 Atherosclerotic lesion characteristics in  APOE(−/−) mice fed with HFD and treated with canagliflozin (Cana‑group) or vehicle (control‑group). 
a Selected 4 μm image sections from the aortic root, immunostained for smooth muscle cells (α‑Actin), MCP‑1, MMP‑9 and MMP‑2, macrophages 
(CD68), and TIMP‑1/TIMP‑2. b Immunostaining differences between groups. Positive cell proportion stained with each antibody was scored from 0 
to 4 and staining intensity from 0 to 3 with 0 representing no visual staining and 4 representing intense staining (> 75% of area). Immunoreactivity 
was scored on a 0–7 scale [extend of staining (0–4) plus intensity of staining (0–3)]. There was a significant difference in MCP‑1 expression between 
Cana‑group and control‑group (P = 0.048). A‑actin and CD68 expression were numerically higher in the Control‑group (P = 0.1). Bar graphs show 
mean ± SD and *P < 0.05. (Original magnification ×200; scale bar, 150 μm)
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metabolic syndrome model rat [26]. It should be men-
tioned that Terasaki et al. [17], showed no differences in 
heart rate following administration of dapagliflozin for 
4 weeks, however their  APOE(−/−) mouse model feeding 
western diet did not increase blood glucose levels, thus 
there were no changes in blood glucose with dapagliflo-
zin administration.
It is well established that inflammatory cytokines and 
adhesion molecules play a crucial role in the initiation 
and progression of atherosclerotic process. Since we 
found that the majority of the mice in Cana-group did not 
form atherosclerotic plaque in contrast to control-group, 
we investigated the expression of ICAM-1, VCAM-
1, IL-6 and MCP-1 between groups and found lower 
mRNA expression of MCP-1 and VCAM-1. A study by 
Oelze et  al. [32] showed that empagliflozin for 6  weeks 
decreased the expression of IL-6 and MCP-1. Moreover, 
luseogliflozin also reduced the expression of ICAM-1 and 
IL-6 while did not affect VCAM-1 [30]. In both studies, 
streptozotocin-induced diabetes models were used.
Interestingly, we additionally confirmed the beneficial 
effect of canagliflozin on MCP-1 expression at the pro-
tein level, in atherosclerotic lesion (plaque). The role of 
MCP-1 in both initiation and progression of atheroscle-
rosis has been well-characterized and various mecha-
nisms have been proposed for this [33]. A potential 
mechanism is by promoting the recruitment of mono-
cytes/macrophages in atherosclerotic lesion. In our study, 
the decreased number of stained macrophages in the 
plaque could be attributed to, among others, decreased 
MCP-1 expression. Moreover, it has been reported that 
MCP-1 induces MMP-2 expression in human endothe-
lial cells, as well as the expression of MMP-9 in human 
smooth muscle cells [34, 35]. Both MMPs are critical fac-
tors involved in plaque destabilization, through degrada-
tion of collagen-rich extracellular matrix.
According to our data, although canagliflozin admin-
istration reduced MCP-1 expression, it did not change 
the MMP-2, MMP-9, while marginally increased TIMP-1 
and TIMP-1/MMP-2 ratio, indicating reduced activity of 
MMP-2.
Previous studies have shown that high glucose concen-
trations decrease the expression of MMPs and increase 
the expression of their inhibitors (TIMPs) [36]. In our 
study, by reducing blood glucose at normal levels, cana-
gliflozin would be expected to lead to the above-men-
tioned profile (increased MMP-2 and MMP-9 expression 
and decreased TIMP-1 and TIMP-2). However, acting via 
decreasing either directly, or indirectly-through lower-
ing blood glucose [37], MCP-1, not only counterbalances 
but rather is associated with a favorable TIMP-1/MMP-2 
profile in the aortic lesion. Another potential mechanism 
that could explain this TIMP-1/MMP-2 profile is the 
reduction of VCAM-1 by canagliflozin which has been 
demonstrated to lead to an up-regulation of TIMP-1 
[38]. This favorable profile could result, along with other 
factors, in increased collagen content demonstrated in 
the plaque of the Cana-group. Of note, another SGLT-2 
inhibitor, luseogliflozin, given for 1  week decreased 
MMP-2 and MMP-9 expression in aorta wall but not in 
atherosclerotic plaque of streptozotocin-induced diabetic 
 APOE(−/−) mice [30].
Attenuation of plaque formation and decreased num-
ber of invasive macrophages has been demonstrated 
following dapagliflozin administration in streptozo-
tocin-induced  APOE(−/−) mice, while no effect has been 
reported in non-diabetic  APOE(−/−) mice [17]. Moreover, 
empagliflozin administration for 8  weeks decreased the 
burden of plaque (plaque area), expression of inflamma-
tory molecules TNF, IL-6 and MCP-1, and invasion of 
plaque by inflammatory cells and this effect was more 
potent in the empagliflozin mice group compared to 
glimepiride-group that achieved the same glycemic con-
trol, the latter suggesting beneficial effects of the SGLT-2i 
other than just improved glycemic control [25].
According to our data, increased staining for 
α-actin (smooth muscle cells) in the control-group 
(4 mice) compared to Cana-group (one mouse with 
plaque)-albeit not statistically significant-could sug-
gest decreased plaque stability in Cana-group, an effect 
contradicting our collagen content findings, requir-
ing further clarification. However, recent studies pro-
pose, a heterogeneous population of cells expressing 
α-actin and 50% of foam cells within advanced human 
coronary artery lesions. These, express α-actin besides 
CD68 (macrophage marker), whereas ≤ 80% of the 
lesion cells (including mesenchymal stem cells and 
macrophage-like cells) are smooth muscle cell-derived 
[39, 40]. An important advantage of this study is that 
we used a mouse model that (1) can develop all stages 
of atherosclerosis process, from endothelium activa-
tion and foam cell stage to plaque vulnerability and 
rupture, and (2) can develop mild diet-induced dia-
betes, thus is a more suitable model for studying dia-
betes and its main complication i.e. atherosclerosis. It 
should be noted that streptozotocin-induced diabetic 
mice (resembling type 1 diabetes), that are used in most 
studies elucidating the effects of other SGLT-2 inhibi-
tors, are characterized by markedly increased glucose 
levels which result in more detrimental effects on vari-
ous inflammatory and metabolic parameters contribut-
ing to atherosclerosis, thus their beneficial effects could 
be more pronounced. Our results showing mitigation 
of atherosclerosis in mice with mild diet-induced dia-
betes, are of great importance. Moreover, two time-
points (before and after the intervention) measurement 
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of biochemical parameters, gave us the chance to com-
pare their changes and not only the values at the end of 
intervention, between the two groups.
Limitations of our study is the small number of mice 
and the fact that the design of this study does not allow 
to draw conclusions around the possible direct effects of 
canagliflozin on atherosclerotic process. Furthermore, 
measurements of serum insulin levels as well as of vis-
ceral fat could add substantially to the elucidation of the 
mechanism via which canagliflozin can reduce atheroma 
burden. Finally, although the significant difference in the 
development of atherosclerosis between our two groups 
substantiates the anti-atherogenic effect of canagliflo-
zin, can at the same time make the interpretation of data 
regarding plaque stability difficult.
Attenuation/inhibition of atherosclerosis in our model 
is mainly attributed to the glucose and lipid-lowering 
effects of canagliflozin. Correlation analysis showed that 
the atherosclerotic area is related to glucose and LDL-
cholesterol range after the intervention; however, direct 
effects of canagliflozin could not be ruled out especially in 
the light of recent studies demonstrating direct effects of 
canagliflozin on human endothelial cells and monocyte/
macrophages, both involved in atherogenesis process 
[9, 10]. Of note, SGLT2 is not detected at mRNA level 
in human endothelial cells, while it remains uncertain if 
SGLT2 protein is present [9]. Thus, whether the above 
anti-inflammatory effects of canagliflozin are associated 
with SGLT2 or SGLT1 which is expressed in endothelial 
cells [41], or another facilitative glucose transporter-as it 
is suggested previously in rat muscle cells-remains unex-
plored and of great interest [21].
In summary, our data provide for the first time, evi-
dence that canagliflozin attenuates atherosclerosis pro-
cess in atherosclerotic mouse model through mechanisms 
that involve (1) improved glycemic control and decreased 
cholesterol and triglycerides, and (2) inflammation pro-
cess via decreasing the MCP-1 and VCAM-1 expression. 
Moreover, canagliflozin seems to increase the stability of 
atherosclerotic plaque and possible mechanisms involve 
decreased MCP-1 expression and increased TIMP-1/
MMP-2 ratio. Further experimental studies with larger 
number of mice per group based on power calculation, 
(including a group of atherosclerotic mice model that do 
not become diabetic with atherogenic diet), longer dura-
tion as well as various doses, will add to current knowl-
edge and importantly will delineate possible direct effects 
of canagliflozin on the atherosclerosis process. Elucida-
tion of the precise molecular mechanisms underpinning 
SGLT2 signalling in cells involved in the atherogenic pro-
cess may prove useful in understanding the role of cana-
gliflozin in the CVD.
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